Goldman Sachs Group Inc Atai Life Sciences N.V. Transaction History

Goldman Sachs Group Inc

  • $780 Billion
  • Q3 2025

A detailed history of Goldman Sachs Group Inc transactions in Atai Life Sciences N.V. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 449,046 shares of ATAI stock, worth $1.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
449,046
Previous 347,868 29.09%
Holding current value
$1.8 Million
Previous $761,000 212.09%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025
BUY
$2.62 - $5.61 $265,086 - $567,608
101,178 Added 29.09%
449,046 $2.38 Million
Q2 2025

Aug 14, 2025
BUY
$1.21 - $2.49 $301,564 - $620,575
249,227 Added 252.66%
347,868 $761,000
Q1 2025

May 09, 2025
SELL
$1.33 - $2.55 $97,024 - $186,025
-72,951 Reduced 42.51%
98,641 $134,000
Q4 2024

Feb 11, 2025
BUY
$1.06 - $1.78 $9,356 - $15,712
8,827 Added 5.42%
171,592 $228,000
Q3 2024

Nov 14, 2024
SELL
$1.16 - $1.64 $39,665 - $56,078
-34,194 Reduced 17.36%
162,765 $188,000
Q2 2024

Aug 13, 2024
SELL
$1.27 - $2.6 $28,395 - $58,133
-22,359 Reduced 10.19%
196,959 $261,000
Q1 2024

May 15, 2024
BUY
$1.5 - $2.19 $161,511 - $235,806
107,674 Added 96.44%
219,318 $432,000
Q4 2023

Feb 13, 2024
BUY
$1.04 - $1.55 $57,202 - $85,253
55,002 Added 97.1%
111,644 $157,000
Q3 2023

May 14, 2024
SELL
$1.27 - $2.28 $69,852 - $125,404
-55,002 Reduced 49.27%
56,642 $73,000
Q3 2023

Nov 14, 2023
SELL
$1.27 - $2.28 $6,922 - $12,428
-5,451 Reduced 8.78%
56,642 $73,000
Q2 2023

May 14, 2024
SELL
$1.44 - $2.19 $50,627 - $76,996
-35,158 Reduced 36.15%
62,093 $106,000
Q2 2023

Aug 14, 2023
SELL
$1.44 - $2.19 $50,627 - $76,996
-35,158 Reduced 36.15%
62,093 $106,000
Q1 2023

May 14, 2024
SELL
$1.17 - $2.7 $14,746 - $34,030
-12,604 Reduced 11.47%
97,251 $176,000
Q1 2023

May 11, 2023
SELL
$1.17 - $2.7 $14,746 - $34,030
-12,604 Reduced 11.47%
97,251 $176,000
Q4 2022

May 14, 2024
SELL
$2.38 - $3.55 $29,664 - $44,247
-12,464 Reduced 10.19%
109,855 $292,000
Q4 2022

Feb 13, 2023
SELL
$2.38 - $3.55 $29,664 - $44,247
-12,464 Reduced 10.19%
109,855 $292,000
Q3 2022

May 14, 2024
SELL
$3.14 - $4.87 $52,883 - $82,020
-16,842 Reduced 12.1%
122,319 $405,000
Q3 2022

Nov 10, 2022
SELL
$3.14 - $4.87 $52,883 - $82,020
-16,842 Reduced 12.1%
122,319 $404,000
Q2 2022

May 14, 2024
BUY
$3.03 - $5.32 $83,376 - $146,390
27,517 Added 24.65%
139,161 $507,000
Q2 2022

Aug 15, 2022
BUY
$3.03 - $5.32 $242,166 - $425,190
79,923 Added 134.92%
139,161 $507,000
Q1 2022

May 16, 2022
SELL
$4.66 - $7.66 $437,508 - $719,166
-93,886 Reduced 61.31%
59,238 $302,000
Q4 2021

Feb 14, 2022
BUY
$6.82 - $17.8 $1.04 Million - $2.73 Million
153,124 New
153,124 $1.17 Million

Others Institutions Holding ATAI

# of Institutions
149
Shares Held
45.8M
Call Options Held
1.88M
Put Options Held
543K
View Full List

About ATAI Life Sciences N.V.

ATAI Quotes by TradingView
  • Ticker ATAI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 165,875,008
  • Market Cap $664M
  • Description
  • Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...
More about ATAI
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email